Q4 2023 Bristol-Myers Squibb Co Earnings Call

Contributing sentiments towards policy:

60% : So let me take a few minutes to tell you about our strategy to navigate our LOEs and be very clear about my focus on execution.
50% : Excluding foreign exchange, we expect revenues to increase in the low single digit as well.
48% : Unless otherwise stated, all comparisons are made versus the same period in 2022, and sales performance growth rates will be discussed on an underlying basis, which excludes the impact of foreign exchange.
44% : We project our tax rate to be approximately 17.5%, reflecting an increase due to nonrecurrence of onetime tax benefit that occurred in the third quarter of last year, plus the anticipated impact of Pillar 2.
43% : So for Eliquis, given the patient mix is largely skewed towards Medicare, do you think there could be a potential uplift that could help offset that pricing erosion?

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.